New drug duo tested in fight against aggressive blood cancers
NCT ID NCT04128748
Summary
This study is testing a combination of two drugs, CPX-351 and quizartinib, to see if they can help control acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The main goals are to find the safest and most effective dose and to see how well the treatment works. The study is for adults with newly diagnosed or returning forms of these blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.